Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ATYR1940

Other · developed by aTyr Pharma

Phase 1/2 Most advanced trial (none active)

ATYR Developer

1 Registered trials

What is ATYR1940?

ATYR1940 is a concentrate for solution for infusion. It is studied in facioscapulohumeral muscular dystrophy and limb girdle muscular dystrophy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Musculoskeletal
Developer: aTyr Pharma, Inc. (ATYR)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: WS7U5TQ7ZJ

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02836418	Phase 1/2	Facioscapulohumeral Muscular Dystrophy	Completed	ATYR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Facioscapulohumeral Muscular DystrophyLimb Girdle Muscular Dystrophy

More from aTyr Pharma

Efzofitimod Phase 3

Sources

ClinicalTrials.gov NCT02836418

Updated Oct 11, 2026. Something wrong or missing? Report it on the ATYR page.

Follow ATYR, the company behind ATYR1940

See ATYR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ATYR catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z